The combined strategy with PPARα agonism and AT1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat

Pharmacological Research

Volumn 66, Issue 4, 2012, Pages 349-356

  Bishnoi, Harish Kumar ^a   Mahadevan, Nanjaian ^a   Balakumar, Pitchai ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

Combination therapy; Diabetes mellitus; Dyslipidemia; Fenofibrate; Hyperglycemia; Nephropathy; Oxidative stress; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHOLESTEROL; CREATINE; FENOFIBRATE; GLUCOSE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NITROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN; STREPTOZOCIN; TELMISARTAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; FEMALE; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; CREATINE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; KIDNEY; LIPIDS; MALE; NITROGEN; OXIDATIVE STRESS; PPAR ALPHA; PROTEINURIA; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 84865038901     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.07.001     Document Type: Article

References (51)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
2. G. Soldatos, and M.E. Cooper Diabetic nephropathy: important pathophysiologic mechanism Diabetes Research and Clinical Practice 82 2008 S75 S79
3. M. Dalla Vestra, A. Saller, E. Bortoloso, M. Mauer, and P. Fioretto Structural involvement in type 1 and type 2 diabetic nephropathy Diabetes and Metabolism 26 2000 8 14 (Pubitemid 30618351)
4. D. de Zeeuw, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, and S. Shahinfar Proteinuria, a target for renoprotection in patient with type 2 diabetic nephropathy: lessons from RENAAL Kidney International 65 2004 2309 2320 (Pubitemid 38670018)
5. G. Wolf, and F.N. Ziyadeh Cellular and molecular mechanism of proteinuria in diabetic nephropathy Nephron Physiology 106 2007 p26 p31
6. Y.S. Kanwar, J. Wada, L. Sun, P. Xie, E.J. Wallner, and S. Chen Diabetic nephropathy: mechanisms of renal disease progression Experimental Biology and Medicine (Maywood) 233 2008 4 11
7. P. Balakumar, M.K. Arora, S.S. Ganti, J. Reddy, and M. Singh Recent advances in pharmacotherapy for diabetic nephropathy: current prospective and future directions Pharmacological Research 60 2009 24 32
8. P. Fioretto, and M. Mauer Histopathology of diabetic nephropathy Seminars in Nephrology 27 2007 195 207 (Pubitemid 46550314)
9. P. Balakumar, V.A. Chakkarwar, P. Krishan, and M. Singh Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomedicine and Pharmacotherapy 63 2009 171 179
10. P. Balakumar, M.K. Arora, J. Reddy, and M.B. Anand-Srivastava Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism Journal of Cardiovascular Pharmacology 54 2009 129 138
11. H.H. Parving, S. Andersen, P. Jacobsen, P.K. Christensen, K. Rossing, and P. Hovind Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points Seminars in Nephrology 24 2004 147 157 (Pubitemid 38387856)
12. P. Ruggenenti, P. Cravedi, and G. Remuzzi The RAAS in the pathogenesis and treatment of diabetic nephropathy Nature Reviews Nephrology 6 2010 319 330
13. M. Dalla Vestra, N. Simioni, and A. Masiero Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy International Urology and Nephrology 41 2009 119 126
14. P. Balakumar, and G. Jagadeesh Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system Journal of Cardiovascular Pharmacology 56 2010 570 579
15. J.C. Rutledge, K.F. Ng, H.H. Aung, and D.W. Wilson Role of triglyceride-rich lipoproteins in diabetic nephropathy Nature Reviews Nephrology 6 2010 361 370
16. C.K. Abrass Cellular lipid metabolism and the role of lipids in progressive renal disease American Journal of Nephrology 24 2004 46 53 (Pubitemid 38258276)
17. R. Trevisan, A.R. Dodesini, and G. Lepore Lipids and renal disease Journal of the American Society of Nephrology 17 2006 S145 S147
18. C. Wanner, and V. Krane Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus Kidney and Blood Pressure Research 34 2011 209 217
19. P. Balakumar, S. Kadian, and N. Mahadevan Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacological Research 65 2012 430 436
20. C.F. Cheng, H.H. Chen, and H. Lin Role of PPARα and its agonist in renal diseases PPAR Research 2010 2010 345098
21. C.W. Park, H.W. Kim, S.H. Ko, H.W. Chung, S.W. Lim, and C.W. Yang Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha Diabetes 55 2006 885 893
22. C.W. Park, Y. Zhang, X. Zhang, J. Wu, L. Chen, and D.R. Cha PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney International 69 2006 1511 1517
23. L. Li, N. Emmett, D. Mann, and X. Zhao Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy Experimental Biology and Medicine (Maywood) 235 2010 383 391
24. F.M. Sacks After the fenofibrate intervention and event lowering in diabetes (FIELD) study: implications for fenofibrate American Journal of Cardiology 102 2008 34L 40L
25. P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacological Research 60 2009 170 173
26. M.K. Arora, K. Reddy, and P. Balakumar The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy European Journal of Pharmacology 636 2010 137 144
27. G. Schernthaner, and R.J. Chilton Cardiovascular risk and thiazolidinediones - what do meta-analyses really tell us? Diabetes, Obesity and Metabolism 12 2010 1023 1035
28. S.C. Benson, H.A. Pershadsingh, C.I. Ho, A. Chittiboyina, P. Desai, and M. Pravenec Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 2004 993 1002 (Pubitemid 38579904)
29. P. Balakumar, H.K. Bishnoi, and N. Mahadevan Telmisartan in the management of diabetic nephropathy: a contemporary view Current Diabetes Reviews 8 2012 183 190
30. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Analytical Biochemistry 95 1979 351 358 (Pubitemid 9194347)
31. G.L. Ellman Tissue sulfhydryl groups Archives of Biochemistry and Biophysics 82 1959 70 77
32. A.F. Boyne, and G.L. Ellman A methodology for analysis of tissue sulfhydryl components Analytical Biochemistry 46 1972 639 653
33. D.R. Finco, and J.R. Duncan Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: a study of 111 cases and a review of related literature Journal of the American Veterinary Medical Association 168 1976 593 601
34. J.L. Lyman Blood urea nitrogen and creatinine Emergency Medicine Clinics of North America 4 1986 223 233 (Pubitemid 16021437)
35. M.D. Morsy, W.N. Hassan, and S.I. Zalat Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats Diabetology & Metabolic Syndrome 2 2010 29
36. A. Remuzzi, S. Puntorieri, M. Alfano, D. Macconi, M. Abbate, and T. Bertani Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury Laboratory Investigation 67 1992 572 579
37. B.F. Schrijvers, and A.S. De Vriese Novel insights in the treatment of diabetic nephropathy Acta Clinica Belgica 62 2007 278 290 (Pubitemid 350253812)
38. Y. Hirasawa, T. Sakai, M. Ito, H. Yoshimura, Y. Feng, and T. Nagamatsu Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway European Journal of Pharmacology 672 2011 159 168
39. J. Thompson, P. Wilson, K. Brandewie, D. Taneja, L. Schaefer, and B. Mitchell Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy American Journal of Pathology 179 2011 1179 1187
40. T. Kuwabara, K. Mori, M. Mukoyama, M. Kasahara, H. Yokoi, and Y. Saito Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice Diabetologia 2012 10.1007/s00125-012-2578-1
41. A. Martínez-Castelao, R. Ramos, M.T. González, and M.J. Castiñeiras Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy Nefrologia 22 2002 51 58
42. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner DAIS Investigators Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo controlled study in type 2 diabetes: results from the diabetes atherosclerosis intervention study (DAIS) American Journal of Kidney Diseases 45 2005 485 493 (Pubitemid 40341327)
43. T.M. Davis, R. Ting, J.D. Best, M.W. Donoghoe, P.L. Drury, and D.R. Sullivan Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study Diabetologia 54 2011 280 290
44. R. Rysavá, V. Tesar, M. Merta The Czech Group for the Study of Glomerulonephritis Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease Blood Pressure Monitoring 10 2005 207 213 (Pubitemid 41192342)
45. A. Barnett Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial Journal of the American Society of Nephrology 17 2006 S132 S135
46. H. Makino, M. Haneda, T. Babazono, T. Moriya, S. Ito, and Y. Iwamoto Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post hoc analysis of the Incipient To Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study Hypertension Research 31 2008 657 664 (Pubitemid 351772856)
47. G. Bakris, E. Burgess, M. Weir, G. Davidai, S. Koval AMADEO Study Investigators Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy Kidney International 74 2008 364 369 (Pubitemid 352002795)
48. P.P. Toth Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary Postgraduate Medicine 122 2010 165 168
49. M.F. McCarty Adjuvant strategies for prevention of glomerulosclerosis Medical Hypotheses 67 2006 1277 1296 (Pubitemid 44442638)
50. E. Dursun, B. Dursun, G. Suleymanlar, and T. Ozben Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus Acta Diabetologica 42 2005 123 128 (Pubitemid 41551999)
51. A.D. Mariee, G.M. Abd-Allah, and M.F. El-Yamany Renal oxidative stress and nitric oxide production in streptozotocin-induced diabetic nephropathy in rats: the possible modulatory effects of garlic (Allium sativum L.) Biotechnology and Applied Biochemistry 52 2009 227 232